1. 1) Stupp R, Hegi ME, Mason WP, et al.: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459–466, 2009
2. 2) Erdem-Eraslan L, van den Bent MJ, Hoogstrate Y, et al.: Identification of patients with recurrent glioblastoma who may benefit from combined bevacizumab and CCNU therapy: a report from the BELOB trial. Cancer Res 76: 525–534, 2016
3. 3) Taal W, Oosterkamp HM, Walenkamp AM, et al.: Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15: 943–953, 2014
4. 4) Wick W, Gorlia T, Bendszus M, et al.: Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377: 1954–1963, 2017
5. 5) Friedman HS, Prados MD, Wen PY, et al.: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733–4740, 2009